MA62992B1 - Formulations de capsules - Google Patents

Formulations de capsules

Info

Publication number
MA62992B1
MA62992B1 MA62992A MA62992A MA62992B1 MA 62992 B1 MA62992 B1 MA 62992B1 MA 62992 A MA62992 A MA 62992A MA 62992 A MA62992 A MA 62992A MA 62992 B1 MA62992 B1 MA 62992B1
Authority
MA
Morocco
Prior art keywords
compound
solid solution
capsule formulations
capsules
suffering
Prior art date
Application number
MA62992A
Other languages
English (en)
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA62992(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx, Inc. filed Critical Chemocentryx, Inc.
Publication of MA62992B1 publication Critical patent/MA62992B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des formulations de capsules en solution solide du composé 1.L'invention concerne également des procédés de traitement d'individus souffrant ou susceptibles de souffrir d'une maladie ou d'un trouble impliquant une activation pathologique des récepteurs C5a, par administration d'une quantité efficace d'une ou de plusieurs capsules de solution solide comprenant le composé 1. L'invention concerne également des capsules de dosage à unité unique comprenant certaines quantités du composé 1, et des kits comprenant une capsule de solution solide comprenant le composé 1.
MA62992A 2018-11-30 2019-11-27 Formulations de capsules MA62992B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
EP23160271.5A EP4233850B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Publications (1)

Publication Number Publication Date
MA62992B1 true MA62992B1 (fr) 2025-01-31

Family

ID=70849818

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54318A MA54318B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules
MA62992A MA62992B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA54318A MA54318B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Country Status (31)

Country Link
US (4) US20200170957A1 (fr)
EP (3) EP4487915A3 (fr)
JP (1) JP7342124B2 (fr)
KR (1) KR102586747B1 (fr)
CN (1) CN113164403A (fr)
AR (1) AR117219A1 (fr)
AU (1) AU2019389031B2 (fr)
BR (1) BR112021010285A2 (fr)
CA (1) CA3120999C (fr)
CL (1) CL2021001389A1 (fr)
CY (1) CY1126079T1 (fr)
DK (2) DK4233850T3 (fr)
ES (2) ES2998858T3 (fr)
FI (2) FI3886820T3 (fr)
HR (2) HRP20241735T1 (fr)
HU (2) HUE069633T2 (fr)
IL (1) IL283450B2 (fr)
LT (2) LT4233850T (fr)
MA (2) MA54318B1 (fr)
MD (2) MD4233850T2 (fr)
MX (1) MX2021006242A (fr)
NZ (1) NZ776554A (fr)
PL (2) PL4233850T3 (fr)
PT (2) PT4233850T (fr)
RS (2) RS64250B1 (fr)
SG (1) SG11202105572UA (fr)
SI (2) SI4233850T1 (fr)
SM (2) SMT202300153T1 (fr)
TW (1) TWI827745B (fr)
WO (1) WO2020112961A1 (fr)
ZA (1) ZA202103820B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4487915A3 (fr) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Formulations de capsules
MX2022005406A (es) 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
MX2023004801A (es) * 2020-10-28 2023-05-10 Chemocentryx Inc Metodos de tratamiento de hidradenitis supurativa.
AU2021410668A1 (en) * 2020-12-21 2023-07-06 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
WO2023225533A1 (fr) * 2022-05-19 2023-11-23 Dow Global Technologies Llc Utilisation de complexes interpolymères à base de peg pour une solubilisation améliorée de médicaments de classe ii bcs
WO2025203055A1 (fr) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Formulation de dihydrofolate encapsulée pour supplémentation alimentaire en tant que supplément nutraceutique efficace et son procédé de préparation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
KR20070084531A (ko) 2004-11-24 2007-08-24 머크 앤드 캄파니 인코포레이티드 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
MX2009012834A (es) * 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
SMT202200074T1 (it) * 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
JP5717768B2 (ja) 2010-03-10 2015-05-13 アッヴィ・バハマズ・リミテッド 固体組成物
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9074470B2 (en) 2010-12-27 2015-07-07 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
MX386859B (es) 2014-02-05 2025-03-19 Lek Pharmaceuticals Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
EP3682879B1 (fr) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
WO2017176620A2 (fr) 2016-04-04 2017-10-12 Chemocentryx, Inc. Antagonistes de c5ar solubles
EP3978523A1 (fr) 2017-04-03 2022-04-06 InflaRx GmbH Traitement de maladies inflammatoires au moyen d'inhibiteurs de l'activité c5a
CA3077395A1 (fr) 2017-10-30 2019-05-09 Chemocentryx, Inc. Composes deuteres utilises comme immunomodulateurs
US20190134020A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
CA3102403A1 (fr) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosage et effet d'un antagoniste de c5a avec une vasculite associee aux anca
EP4487915A3 (fr) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Formulations de capsules

Also Published As

Publication number Publication date
BR112021010285A2 (pt) 2021-08-17
RS64250B1 (sr) 2023-06-30
PL4233850T3 (pl) 2025-03-17
HUE062551T2 (hu) 2023-11-28
US20220233453A1 (en) 2022-07-28
US20250375385A1 (en) 2025-12-11
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
US20240299306A1 (en) 2024-09-12
CY1126079T1 (el) 2023-11-15
CA3120999C (fr) 2025-04-01
SI4233850T1 (sl) 2025-03-31
EP4233850A3 (fr) 2023-09-20
DK4233850T3 (da) 2025-01-02
ZA202103820B (en) 2026-03-25
AU2019389031B2 (en) 2023-06-15
WO2020112961A1 (fr) 2020-06-04
KR102586747B1 (ko) 2023-10-06
AR117219A1 (es) 2021-07-21
SI3886820T1 (sl) 2023-07-31
CA3120999A1 (fr) 2020-06-04
ES2943492T3 (es) 2023-06-13
TW202038952A (zh) 2020-11-01
AU2019389031A1 (en) 2021-06-17
RS66362B1 (sr) 2025-01-31
SG11202105572UA (en) 2021-06-29
EP4233850B1 (fr) 2024-10-02
US20200170957A1 (en) 2020-06-04
CN113164403A (zh) 2021-07-23
KR20210098489A (ko) 2021-08-10
EP4487915A2 (fr) 2025-01-08
PT3886820T (pt) 2023-05-24
EP3886820A1 (fr) 2021-10-06
EP3886820B1 (fr) 2023-04-12
JP2022510304A (ja) 2022-01-26
IL283450B2 (en) 2024-06-01
PT4233850T (pt) 2024-12-30
HRP20241735T1 (hr) 2025-02-28
JP7342124B2 (ja) 2023-09-11
ES2998858T3 (en) 2025-02-21
FI4233850T3 (fi) 2024-12-30
SMT202300153T1 (it) 2023-09-06
IL283450B1 (en) 2024-02-01
HUE069633T2 (hu) 2025-04-28
CL2021001389A1 (es) 2021-12-24
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
EP3886820A4 (fr) 2022-08-24
NZ776554A (en) 2024-12-20
HRP20230551T1 (hr) 2023-08-18
EP3886820B8 (fr) 2023-05-17
EP4233850A2 (fr) 2023-08-30
IL283450A (en) 2021-07-29
MA54318A (fr) 2021-10-06
DK3886820T3 (da) 2023-05-15
MA54318B1 (fr) 2023-08-31
MX2021006242A (es) 2021-09-10
FI3886820T3 (fi) 2023-05-25
TWI827745B (zh) 2024-01-01
LT3886820T (lt) 2023-06-12
MD4233850T2 (ro) 2025-02-28
EP4487915A3 (fr) 2025-03-19
MD3886820T2 (ro) 2023-07-31

Similar Documents

Publication Publication Date Title
MA54318B1 (fr) Formulations de capsules
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA44037B1 (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CA3156269A1 (fr) Inhibiteurs de facteur d du complement oral
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
Moore et al. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
MA31446B1 (fr) Inhibiteurs de raf pour le traitement du cancer de la thyroide
EA202191063A1 (ru) Новая дозированная форма
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
MA53521B1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
MA34327B1 (fr) Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes
MA35882B1 (fr) Inhibiteurs de pde9 comprenant un squelette imidazotriazinone
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations
MA47053A1 (fr) Utilisation d'anticorps anti-c1s dans la fabrication d'un medicament destiné au traitement de maladies et de troubles a mediation par le complément.